Sensex Breaks Two-Day Rising Streak, Nifty Settles At 10,767. 10 Points To Know
- Sun Pharma, Lupin, Cipla, Tata Motors and Dr Reddy's were leading the pack of Nifty gainers. While the main losers on NSE were Hindalco, Powergrid, HDFC and BPCL.
- In the 30-shareSensex pack, the main gainers were Sun Pharma, Tata Motors, TCS and Infosys. The losers were Wipro, Powergrid, Tata Steel, Yes Bank and ICICI Bank.
- Asian shares also fell today as risk appetite soured on bets that Europe's massive monetary stimulus was nearing an end.
- "Last week, we saw strong grubbing in the indexes and mid-cap space after which there was a bounce-back. Now, the markets are back to normal, with some kind of profit-booking post yesterday's gains," said Siddharth Sedani, vice president - head equity advisory at Anand Rathi.
- HDFC and Larsen & Toubro Ltd were among the top drag on both indexes, dropping as much as 1.1 per cent each. Oil marketing firms Bharat Petroleum Corp Ltd and Hindustan Petroleum Corp Ltd fell, hurt by higher oil prices on Venezuela's supply struggles and ongoing output cuts led by OPEC.
- The Nifty pharma index rose as much as 2.9 per cent, but looked set to post a weekly gain, its second in three weeks. Shares of Sun Pharmaceutical Industries Ltd closed 8 per cent higher after the U.S. Food and Drug Administration issued VAI status to the drugmaker's Halol plant.
- Dr.Reddy's Laboratories Ltd rose 3.3 per cent. Both stocks led gains on the NSE index.Â
- Shares of Housing finance companies have been correcting on margin concerns due to rising bond yields, according to brokerage firm Jefferies.
- The index had gained 559.87 points in the past two sessions after the RBI hiked the policy rate on inflation concerns but maintained its neutral stance and growth outlook.Â
- Meanwhile, on a net basis, foreign portfolio investors (FPIs) sold shares worth Rs 525.40 crore on Thursday, while domestic institutional investors (DIIs) bought equities to the tune of Rs 1,197.89 crore, as per provisional data. (With inputs from Agencies)
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
